ME03075B - Prolaktin receptor vezujući proteini i njihova upotreba - Google Patents

Prolaktin receptor vezujući proteini i njihova upotreba

Info

Publication number
ME03075B
ME03075B MEP-2018-146A MEP2018146A ME03075B ME 03075 B ME03075 B ME 03075B ME P2018146 A MEP2018146 A ME P2018146A ME 03075 B ME03075 B ME 03075B
Authority
ME
Montenegro
Prior art keywords
prolaktin
binding proteins
receptor binding
receptor
proteins
Prior art date
Application number
MEP-2018-146A
Other languages
German (de)
English (en)
French (fr)
Inventor
Mark Anderson
Jieyi Wang
Archana Thakur
Debra Chao
Chung-Ming Hsieh
Qian Zhang
Edward B Reilly
Enrico L Digiammarino
Kenton L Longenecker
Russell A Judge
David A Egan
Charles W Hutchins
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ME03075B publication Critical patent/ME03075B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00—Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/86—Combinations of radar systems with non-radar systems, e.g. sonar, direction finder
    • G01S13/867—Combination of radar systems with cameras
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00—Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/88—Radar or analogous systems specially adapted for specific applications
    • G01S13/91—Radar or analogous systems specially adapted for specific applications for traffic control
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/50—Context or environment of the image
    • G06V20/56—Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle
    • G06V20/58—Recognition of moving objects or obstacles, e.g. vehicles or pedestrians; Recognition of traffic objects, e.g. traffic signs, traffic lights or roads
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/01—Detecting movement of traffic to be counted or controlled
    • G08G1/0104—Measuring and analyzing of parameters relative to traffic conditions
    • G08G1/0125—Traffic data processing
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/01—Detecting movement of traffic to be counted or controlled
    • G08G1/015—Detecting movement of traffic to be counted or controlled with provision for distinguishing between two or more types of vehicles, e.g. between motor-cars and cycles
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/01—Detecting movement of traffic to be counted or controlled
    • G08G1/04—Detecting movement of traffic to be counted or controlled using optical or ultrasonic detectors
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/01—Detecting movement of traffic to be counted or controlled
    • G08G1/042—Detecting movement of traffic to be counted or controlled using inductive or magnetic detectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Radar, Positioning & Navigation (AREA)
  • Remote Sensing (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Electromagnetism (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Multimedia (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MEP-2018-146A 2012-12-24 2013-12-23 Prolaktin receptor vezujući proteini i njihova upotreba ME03075B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745707P 2012-12-24 2012-12-24
PCT/US2013/077452 WO2014105810A1 (en) 2012-12-24 2013-12-23 Prolactin receptor binding proteins and uses thereof
EP13821368.1A EP2935331B1 (en) 2012-12-24 2013-12-23 Prolactin receptor binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
ME03075B true ME03075B (me) 2019-01-20

Family

ID=49956483

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-146A ME03075B (me) 2012-12-24 2013-12-23 Prolaktin receptor vezujući proteini i njihova upotreba

Country Status (28)

Country Link
US (4) US9725515B2 (me)
EP (2) EP2935331B1 (me)
JP (3) JP6382221B2 (me)
KR (1) KR20150100881A (me)
CN (1) CN105102480B (me)
AU (3) AU2013370548B2 (me)
BR (1) BR112015015289A2 (me)
CA (1) CA2896058A1 (me)
CY (1) CY1120286T1 (me)
DK (1) DK2935331T3 (me)
ES (1) ES2671506T3 (me)
HR (1) HRP20180822T1 (me)
HU (1) HUE037586T2 (me)
IL (1) IL239502B (me)
LT (1) LT2935331T (me)
ME (1) ME03075B (me)
MX (2) MX382301B (me)
NO (1) NO2968312T3 (me)
PL (1) PL2935331T3 (me)
PT (1) PT2935331T (me)
RS (1) RS57259B1 (me)
RU (2) RU2664463C2 (me)
SG (1) SG11201504943QA (me)
SI (1) SI2935331T1 (me)
TR (1) TR201807416T4 (me)
TW (3) TWI646106B (me)
WO (1) WO2014105810A1 (me)
ZA (1) ZA201504803B (me)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
RU2016119491A (ru) 2013-11-04 2017-12-11 Пфайзер Инк. Конъюгаты антитела к efna4 с лекарственным средством
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
HK1247933A1 (en) 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
CA3002097A1 (en) * 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN106265480A (zh) * 2016-09-03 2017-01-04 山西纳安生物科技有限公司 纳米抗体阴道给药系统及制备方法和应用
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
CA3042428A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2019006131A (es) * 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
TWI791006B (zh) 2016-12-26 2023-02-01 日商Ｊｃｒ製藥股份有限公司 包含bdnf之融合蛋白質
MX2019007824A (es) * 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
SG11201906404RA (en) * 2017-03-20 2019-08-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
WO2018195008A1 (en) * 2017-04-21 2018-10-25 Mellitus, Llc Methods and antibodies for diabetes-related applications
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
WO2018213592A1 (en) * 2017-05-19 2018-11-22 J. Craig Venter Institute Compositions and methods for resolution of inflammation
MY205541A (en) * 2017-08-03 2024-10-25 Alector Llc Anti-cd33 antibodies and methods of use thereof
CA3247730A1 (en) 2017-11-07 2025-10-30 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
MA50259A1 (fr) 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
KR102832008B1 (ko) * 2018-07-31 2025-07-10 컬리난 미카 코퍼레이션 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
US12454574B2 (en) 2018-10-30 2025-10-28 Board Of Regents, The University Of Texas System Anti-CD79B antibodies and chimeric antigen receptors and methods of use thereof
MX2021010766A (es) * 2019-03-12 2021-12-10 Univ Health Network Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
EP3757217A1 (en) * 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
CA3147122A1 (en) * 2019-07-12 2021-01-21 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Cldn18.2 antibody and use thereof
RU2722398C1 (ru) * 2019-08-09 2020-05-29 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к БТШ70
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US20230183371A1 (en) * 2020-04-30 2023-06-15 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
MX2022015769A (es) * 2020-06-24 2023-01-19 Regeneron Pharma Tubulisinas y conjugados de proteina-tubulisina.
US20230226175A1 (en) 2020-06-25 2023-07-20 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
KR102895290B1 (ko) * 2020-12-10 2025-12-03 현대자동차주식회사 사륜 구동 전동화 차량의 변속 시 구동 제어 장치
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CA3217279A1 (en) * 2021-05-04 2022-11-10 Olga Ignatovich Anti-tigit antibodies and methods of use thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
JP2024522237A (ja) * 2021-06-18 2024-06-11 セリーニ バイオ インコーポレイテッド ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法
AU2022375785A1 (en) * 2021-10-27 2024-04-11 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN115353541B (zh) * 2022-09-01 2024-06-18 英科新创（苏州）生物科技有限公司 雌二醇衍生物的制备方法，中间体、其制备方法和应用
CN115417908B (zh) * 2022-09-01 2024-06-18 英科新创（苏州）生物科技有限公司 雌二醇衍生物、其制备方法、检测试剂盒及雌二醇定量检测方法
CN117694469B (zh) * 2024-02-02 2024-04-23 潍坊新希望六和饲料科技有限公司 一种改善褐壳鸡蛋蛋壳质量的饲料添加剂
WO2025188901A1 (en) 2024-03-05 2025-09-12 Halozyme, Inc. Combination therapy with antibody-drug conjugates and hyaluronidases
CN121620535A (zh) * 2024-05-27 2026-03-06 杭州阿诺生物医药科技有限公司 一种多功能融合蛋白
WO2025250777A1 (en) * 2024-05-30 2025-12-04 Jecho Laboratories, Inc. Prolactin receptor (prlr)-specific antibody and uses thereof
CN118506590B (zh) * 2024-06-03 2025-10-10 中山大学 基于强化学习的交通协同信号控制方法和系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867187B2 (en) 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
US7507716B2 (en) 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
CA2661023C (en) 2006-08-18 2017-08-15 Novartis Ag Prlr-specific antibody and uses thereof
CA2753804C (en) 2009-02-26 2018-03-13 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
US20130244936A1 (en) 2010-06-04 2013-09-19 Vincent Goffin Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
WO2012136519A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses

Also Published As

Publication number Publication date
HUE037586T2 (hu) 2018-09-28
AU2019202725A1 (en) 2019-05-16
ZA201504803B (en) 2020-02-26
WO2014105810A1 (en) 2014-07-03
JP6382221B2 (ja) 2018-08-29
IL239502A0 (en) 2015-08-31
PL2935331T3 (pl) 2018-07-31
MX382301B (es) 2025-03-13
AU2021202954A1 (en) 2021-06-03
JP2018198608A (ja) 2018-12-20
CN105102480B (zh) 2019-04-16
HK1216257A1 (en) 2016-10-28
EP2935331A1 (en) 2015-10-28
HRP20180822T1 (hr) 2018-08-10
MX359532B (es) 2018-10-01
NO2968312T3 (me) 2018-06-30
TW201920245A (zh) 2019-06-01
CY1120286T1 (el) 2019-07-10
CN105102480A (zh) 2015-11-25
KR20150100881A (ko) 2015-09-02
TR201807416T4 (tr) 2018-06-21
SI2935331T1 (en) 2018-06-29
LT2935331T (lt) 2018-06-25
TW201920283A (zh) 2019-06-01
US20190153110A1 (en) 2019-05-23
ES2671506T3 (es) 2018-06-06
PT2935331T (pt) 2018-06-04
JP2016504035A (ja) 2016-02-12
US20170022281A1 (en) 2017-01-26
RU2015130605A (ru) 2017-01-24
US10184003B2 (en) 2019-01-22
US20210312797A9 (en) 2021-10-07
AU2013370548B2 (en) 2019-01-17
MX2015008299A (es) 2016-02-11
TW201441259A (zh) 2014-11-01
EP3363817A1 (en) 2018-08-22
US9725515B2 (en) 2017-08-08
RU2018129572A (ru) 2018-10-12
TWI646106B (zh) 2019-01-01
EP2935331B1 (en) 2018-02-28
RS57259B1 (sr) 2018-08-31
SG11201504943QA (en) 2015-07-30
RU2664463C2 (ru) 2018-08-17
US20210074147A1 (en) 2021-03-11
BR112015015289A2 (pt) 2017-08-15
AU2013370548A1 (en) 2015-07-09
IL239502B (en) 2019-11-28
DK2935331T3 (en) 2018-06-06
JP2020188775A (ja) 2020-11-26
CA2896058A1 (en) 2014-07-03
US20140227294A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
IL288203A (en) Meditopes and meditope-binding antibodies and uses thereof
IL269045A (en) Aptamers and uses thereof
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
HUE037586T2 (hu) Prolaktin receptor kötõ proteinek és alkalmazásaik
IL238847A0 (en) Recombinant adenoviruses and use thereof
DK2812356T3 (da) CDIM-bindende proteiner og anvendelser deraf
IL236874A0 (en) Anti-kit antibodies and uses thereof
HUE037700T2 (hu) OX40-hez kötõdõ ellenanyagok és felhasználásuk
PL3409683T3 (pl) Spoiwa i powiązane produkty
DK2970464T3 (da) Anti-lag-3-bindende proteiner
PT3199552T (pt) Anticorpos anti-ceacam5 e suas utilizações
BR112015003838A2 (pt) formulações de anticorpo e proteína
DK2850103T3 (da) ST2-antigenbindende proteiner
ME03512B (me) Cd47 antitijela i postupci za njihovu upotrebu
HUE054444T2 (hu) Prolinnal lezárt kapcsos peptidek és felhasználásuk
DK3431492T3 (da) Humane cd30-ligandantigen-bindende proteiner
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
BR112014000049A2 (pt) pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
CL2014003372A1 (es) Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
EP2855506A4 (en) PEPTIDE AND USE THEREOF